Novartis (LSE:0QLR) - Stock Price, News & Analysis

0QLR Stock Overview

Novartis AG investiga, desarrolla, fabrica y comercializa productos sanitarios en Suiza y a escala internacional.

0QLR fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	4/6
Financial Health	5/6
Dividends	4/6

Rewards

Cotiza un 55.7% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 9.85%

Los beneficios aumentaron un 41.6% el año pasado

Trading a buen valor en comparación con empresas similares e industria

Risk Analysis

El dividendo de 3.61% no está bien cubierto por los beneficios

Grandes partidas extraordinarias que afectan a los resultados financieros

Novartis AG Competitors

AstraZeneca

LSE:AZN

UK£166.0b

GSK

LSE:GSK

UK£66.0b

Hikma Pharmaceuticals

LSE:HIK

UK£4.0b

HUTCHMED (China)

AIM:HCM

UK£2.4b

Price History & Performance

Summary of all time highs, changes and price drops for Novartis
Historical stock prices
Current Share Price	CHF86.31
52 Week High	CHF94.77
52 Week Low	CHF83.05
Beta	0.47
1 Month Change	-1.23%
3 Month Change	-5.62%
1 Year Change	-0.85%
3 Year Change	8.02%
5 Year Change	6.57%
Change since IPO	19.84%

Recent updates

Shareholder Returns

	0QLR	GB Pharmaceuticals	GB Market
7D	0.6%	-2.0%	-0.01%
1Y	-0.8%	-4.9%	0.8%

Rentabilidad frente al sector: 0QLR superó al sector UK Pharmaceuticals , que obtuvo un rendimiento del -3.3% el año pasado.

Rentabilidad vs. Mercado: 0QLR obtuvo unos resultados inferiores a los del mercado UK, que fue del 0.8% el año pasado.

Price Volatility

Is 0QLR's price volatile compared to industry and market?
0QLR volatility
0QLR Average Weekly Movement	2.1%
Pharmaceuticals Industry Average Movement	8.5%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0QLR no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0QLR (2%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
1996	76,057	Vas Narasimhan	https://www.novartis.com

Novartis AG investiga, desarrolla, fabrica y comercializa productos sanitarios en Suiza y a escala internacional. Ofrece medicamentos de prescripción para pacientes y médicos. Se centra en áreas terapéuticas como cardiovascular, renal y metabólica, inmunología, neurociencia y oncología, así como oftalmología y hematología.

Novartis AG Fundamentals Summary

How do Novartis's earnings and revenue compare to its market cap?
0QLR fundamental statistics
Market cap	CHF189.14b
Earnings (TTM)	CHF7.74b
Revenue (TTM)	CHF42.15b

24.4x

P/E Ratio

4.5x

P/S Ratio

Is 0QLR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QLR income statement (TTM)
Revenue	US$46.66b
Cost of Revenue	US$12.02b
Gross Profit	US$34.64b
Other Expenses	US$26.07b
Earnings	US$8.57b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 23, 2024

Earnings per share (EPS)	3.91
Gross Margin	74.24%
Net Profit Margin	18.36%
Debt/Equity Ratio	52.6%

How did 0QLR perform over the long term?

See historical performance and comparison

Dividends

3.8%

Current Dividend Yield

95%

Payout Ratio

0QLR Stock Overview

Rewards

Risk Analysis

Novartis AG Competitors

LSE:AZN

UK£166.0b

LSE:GSK

UK£66.0b

LSE:HIK

UK£4.0b

AIM:HCM

UK£2.4b

Price History & Performance

Recent News & Updates

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Upcoming dividend of CHF3.30 per share

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Recent updates

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Upcoming dividend of CHF3.30 per share

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Final dividend of CHF3.30 announced

New minor risk - Earnings quality

Novartis AG Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$4.13 (vs US$3.19 in FY 2022)

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Third quarter 2023 earnings released: EPS: US$0.73 (vs US$0.73 in 3Q 2022)

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Novartis AG Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Novartis AG Announces Executive Changes

Novartis Presents New Long-Term Leqvio (Inclisiran) Data Demonstrating Consistent Efficacy and Safety Beyond Six Years

Sandoz Announces Positive Results from Mylight Phase III Study for Biosimilar Aflibercept

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Novartis Ag Announces Positive Top-Line Results from the Phase Iii Remix-1 and Remix-2 Studies Evaluating Remibrutinib 25 Mg B.I.D

Second quarter 2023 earnings released: EPS: US$1.11 (vs US$0.77 in 2Q 2022)

Novartis AG (SWX:NOVN) acquired DTx Pharma, Inc. for $1 billion.

US FDA Approves Expanded Indication for Novartis Leqvio® (Inclisiran) to Include Treatment of Adults with High LDL-C and Who Are at Increased Risk of Heart Disease